Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
about
Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XREfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisUnderstanding and overcoming metformin gastrointestinal intolerance.Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientA systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapyA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesThe influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.Dapagliflozin efficacy and safety: a perspective review.DapagliflozinPlace of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetesDapagliflozin for the treatment of type 2 diabetes: a review of the literatureSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsDapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsThe efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetesDiurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 DiabetesRenal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusThe potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusCardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Cystatin C- and Creatinine-Based Estimates of Glomerular Filtration Rate in Dapagliflozin Phase 3 Clinical TrialsEfficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment periodLong-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesClinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes.Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies
P2860
Q26752815-6C1047C9-0B66-4321-9822-C50A607AEF35Q26766404-A19BFDFD-8216-4A64-8E02-8E3F97D853A3Q26782225-2DC7453F-8A16-4680-A3F1-38D2C04C3902Q26864336-1D736A86-E845-47B0-B9E6-84048EDCFEE4Q28072765-BAE35953-EB3F-42E2-A275-974287F4BB33Q28076978-5384D1D1-7B2D-48A7-8F5A-53400F51A1C5Q28553482-9B32107B-95B4-4A50-BC94-2B2F6EF7DD84Q30240030-BEA43315-60F3-43E8-B947-067C9CF05343Q30248634-2B50B937-B773-4AFB-87BB-8FC6B6AFBC52Q30877953-1F5256C2-E4DC-458E-A0C4-3813DE26E070Q33166813-0C5B2C88-C3F5-403E-B348-6B47A8694584Q33759570-E0D50955-F24C-461E-902E-B1BE0DE2F229Q33859245-29FB1CD8-1BD3-4109-B556-347CCEC9D844Q34161881-C941091A-6D94-4D4C-9733-1414F566583AQ34198692-2B554006-EECF-4E6F-9C76-51EB71F5E272Q34315521-366FC630-CD7C-4F5D-830A-6279D7CC0F32Q34514280-BA29774D-C366-4A08-AE25-0DC9AB42099AQ34613015-FC980000-2ECD-4243-861A-48D92DD0B131Q34699217-4C9F664A-7F99-4ADD-B39D-8AFA3E828472Q34710819-0B7F4FCA-E03B-4555-B8E7-8609B17EFA1AQ34973750-55D3C973-A341-4328-A767-217FC016A174Q35014111-E802DB36-7597-4C41-8BA1-94740E7966CDQ35068181-73370482-E8D6-4009-93CF-3CD0A9F5DA96Q35141884-FEA9C6C2-2A0A-4BE9-AFB9-30F5A558F304Q35780861-4237F300-A57C-4C80-8C6F-0FE1174775C2Q35906490-331113C9-89D4-4BE3-8535-E5FCBB33DDA0Q35973288-95E681E4-53C8-4B45-A164-5FFD598095A9Q36180337-7B4D086C-4600-491C-9462-5F7E2EBE4883Q36221586-46C0DF53-4F75-4C3E-B237-E6C145468D78Q36257199-568B3F80-07A0-4C21-B854-6B05F01A21AFQ36345951-238347C9-B97D-48CE-B07B-BC53724D1F45Q36592820-ED734F3F-68EE-4FA6-A291-EEFDFC9BB9A9Q36599869-6C92BCEF-9270-49E4-A0A9-611A7145252EQ36712221-DF64303E-16FC-46CE-AA5B-9870493AB91DQ37060860-1DEDAE5A-1712-4384-87EB-191D33FA66BAQ37075620-FE783387-D91A-46F3-8F6F-B6E7C157079EQ37154927-B69BC089-E393-46CD-B8B5-EF7820B00611Q37244327-AFCE7ECF-2552-454B-B86C-8C7832460AE8Q37343916-9AC1713A-4E26-4032-94E4-1E60F71740D1Q37354187-39CAAE22-11A9-4DCE-B872-4099C77BAA5F
P2860
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@en
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@nl
type
label
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@en
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@nl
prefLabel
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@en
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@nl
P2093
P2860
P921
P1476
Dapagliflozin, metformin XR, o ...... a randomised controlled trial.
@en
P2093
A Ptaszynska
A V Murray
D Hennicken
M H Marmolejo
P2860
P304
P356
10.1111/J.1742-1241.2012.02911.X
P577
2012-03-13T00:00:00Z